A pharmaceutical company representative described the Access to Medicine Index 2016 as “a force for good, and not yet another stick with which to beat industry”.1 The Access to Medicine Index 2016,1 which will be presented at a public meeting later this month at the time of the WHO Executive Board meeting in Geneva, ranks the top 20 research-based pharmaceutical companies on their efforts to improve access to medicine in low-income and middle-income countries (LMICs). And those companies with high ranking tout their success to their stockholders and the media.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iPVL7x
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
We are excited to share with you the newest dentistry and patient safety editions recently added to STAT!Ref. As a reminder, all STAT!Ref c...
-
Abstract Sexual dimorphism in the human respiratory system has been previously reported at the skeletal (cranial and thoracic) level, but ...
-
Abstract The effects of oxygen addition on a helium-based flowing atmospheric pressure afterglow (FAPA) ionization source are explored. Sm...
-
Objective Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. Ho...
-
2016-12-10T02-17-59Z Source: Indo American Journal of Pharmaceutical Research M.R. Pradeep Kumar*, Shrinivas D. Joshi . With an objecti...
-
http://ift.tt/2svTdo9
-
The evaluation of mineral resources development efficiency is a typical multicriteria decision-making issue. Meanwhile, due to the limited e...
-
Photochem. Photobiol. Sci. , 2018, Accepted Manuscript DOI : 10.1039/C7PP00350A, Paper Yan Xie, Jianrong Gao, Shaozheng Zhang, Liang Wu F...
-
Background: Inferring the topology of gene regulatory networks (GRNs) from microarray gene expression data has many potential applications, ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου